Compounds > 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Page last updated: 2024-08-25

5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Lymphoma

5-(3-methyl-1-triazeno)imidazole-4-carboxamide has been researched along with Lymphoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gescher, A; Quarterman, CP; Slack, JA; Tsang, LL1

Other Studies

1 other study(ies) available for 5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Lymphoma

ArticleYear
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
    Cancer chemotherapy and pharmacology, 1991, Volume: 27, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Lymphoma; Mice; Prodrugs; Temozolomide; Tumor Cells, Cultured

1991